TP53 and colorectal cancer: In a humanized mouse colorectal cancer model, a vaccine produced by using a mixture of long peptides derived from KRAS and TP53 mutant proteins combined with MHC molecules was found to induce strong cytotoxicity and T helper cell immune responses to multiple mutations at the same time [67].